Giuseppe Giannini

Dr. Giuseppe Giannini

Alfasigma (Italy), Bologna, Emilia-Romagna, Italy
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2018 in Chemical Science
Verified
Journal Article
Open access
PDF file
ECElena Cini
Elena Cini
VFValentina Faltoni
Valentina Faltoni
EPElena Petricci
Elena Petricci
MTMaurizio Taddei
Maurizio Taddei
LSLaura Salvini
Laura Salvini
RSRita De Santis
Rita De Santis
We describe here two novel antibody-drug conjugates loaded with the HDAC inhibitor ST7612AA1 (IC50 equal to 0.07 μM on NCI-H460 cells), a thiol-based molecule with a moderate toxicity in vivo. Two payloads were prepared using cleavable and non-cleavable linkers. After anchoring to cetuximab through amide bond with lysines, the resulting HDAC inhibitor-antibody conjugates showed ability to recognize EGFR and efficient internalization in tumor cells. Both ADCs induced sensible increment of histones 3 and 4 and alpha-tubulin acetylation. Animal models of human solid tumors showed high anti-tumor efficacy of the conjugates without the toxicity generally observed with traditional ADCs delivering highly potent cytotoxic drugs. These compounds, the first ADCs charged with not highly cytotoxic warheads, are potentially suitable for epigenetic modulation, extending the ADC strategy to the targeted delivery of HDAC inhibitors with many possible therapeutic applications beyond cancer.

16 July 2018 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Valentina Noemi MadiaValentina Noemi Madia
Valentina Noemi Madia
AMAntonella Messore
Antonella Messore
LPLuca Pescatori
Luca Pescatori
Francesco SaccolitiFrancesco Saccoliti
Francesco Saccoliti
VTValeria Tudino
Valeria Tudino
GGGiuseppe Giannini
Giuseppe Giannini

25 March 2020 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Fabrizio ManettiFabrizio Manetti
Fabrizio Manetti
BSBarbara Stecca
Barbara Stecca
RSRoberta Santini
Roberta Santini
LMLuisa Maresca
Luisa Maresca
GGGiuseppe Giannini
Giuseppe Giannini
EPElena Petricci
Elena Petricci

1 March 2015 in Biochemical Pharmacology
Verified
Journal Article
Closed access
VZValentina Zuco
Valentina Zuco
GCGiuliana Cassinelli
Giuliana Cassinelli
GCGiacomo Cossa
Giacomo Cossa
Laura GattiLaura Gatti
Laura Gatti
EFEnrica Favini
Enrica Favini
Paola PeregoPaola Perego
Paola Perego

1 January 2020 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
DPDaniele Pala
Daniele Pala
LSLaura Scalvini
Laura Scalvini
Gian Marco ElisiGian Marco Elisi
Gian Marco Elisi
ALAlessio Lodola
Alessio Lodola
Marco MorMarco Mor
Marco Mor
GGGiuseppe Giannini
Giuseppe Giannini
Heparanase is a validated target in cancer therapy and a potential target for several inflammatory pathologies. A ligand-based virtual screening of commercial libraries was performed to expand the ...

12 January 2021 in Chemical Communications
Verified
Journal Article
Open access
PDF file
CCClaudio Cianferotti
Claudio Cianferotti
VFValentina Faltoni
Valentina Faltoni
ECElena Cini
Elena Cini
EEElena Ermini
Elena Ermini
FMFrancesca Migliorini
Francesca Migliorini
GGGiuseppe Giannini
Giuseppe Giannini
Antitumor hydroxamates SAHA and Dacinostat have been linked to cetuximab and trastuzumab through a non-cleavable linker based on the p-mercaptobenzyl alcohol structure. These antibody drug conjugates (ADCs) were able to inhibit HDAC in several tumour cell lines. The cetuximab based ADCs block human lung adenocarcinoma cell proliferation, demonstrating that bioconjugation with antibodies is a suitable approach for targeted therapy based on hydroxamic acid-containing drugs. This work also shows that ADC-based delivery might be used to overcome the classical pharmacokinetic problems of hydroxamic acids.